Roderick A. Slavcev, Ph.D.
Affiliations: | 2002 | University of Saskatchewan, Saskatoon, SK, Canada |
Area:
Microbiology BiologyGoogle:
"Roderick Slavcev"Parents
Sign in to add mentorSidney Hayes | grad student | 2002 | University of Saskatchewan | |
(The bacteriophage lambda Rex-centric mutualism phenotype, conditional Rex, and other novel Rex phenotypes.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Slavcev RA, Sum CH, St Jean J, et al. (2018) Specific Systems for Evaluation. Experientia Supplementum (2012). 110: 99-123 |
Wong S, Lam P, Nafissi N, et al. (2016) Production of Double-stranded DNA Ministrings. Journal of Visualized Experiments : Jove |
Sum CH, Nafissi N, Slavcev RA, et al. (2015) Physical Characterization of Gemini Surfactant-Based Synthetic Vectors for the Delivery of Linear Covalently Closed (LCC) DNA Ministrings. Plos One. 10: e0142875 |
Wong S, Slavcev RA. (2015) 577. DNA Ministrings: Linear-Covalently Closed Minivectors for Use in Non-Viral Gene Therapy with Applications Toward Ovarian Cancer Molecular Therapy. 23: S229-S230 |
Sum CH, Wettig S, Slavcev RA. (2014) Impact of DNA vector topology on non-viral gene therapeutic safety and efficacy. Current Gene Therapy. 14: 309-29 |
Nafissi N, Alqawlaq S, Lee EA, et al. (2014) DNA ministrings: highly safe and effective gene delivery vectors. Molecular Therapy. Nucleic Acids. 3: e165 |
Nafissi N, Sum CH, Wettig S, et al. (2014) Optimization of a one-step heat-inducible in vivo mini DNA vector production system. Plos One. 9: e89345 |
Nicastro J, Sheldon K, Slavcev RA. (2014) Bacteriophage lambda display systems: developments and applications. Applied Microbiology and Biotechnology. 98: 2853-66 |
Nafissi N, Slavcev R. (2014) Bacteriophage recombination systems and biotechnical applications. Applied Microbiology and Biotechnology. 98: 2841-51 |
Slavcev R, Sum CH, Nafissi N. (2014) Optimized production of a safe and efficient gene therapeutic vaccine versus HIV via a linear covalently closed DNA minivector Bmc Infectious Diseases. 14 |